Northland Capmk Forecasts MiMedx Group Q1 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG) – Stock analysts at Northland Capmk issued their Q1 2025 EPS estimates for MiMedx Group in a research report issued on Friday, December 27th. Northland Capmk analyst C. Byrnes forecasts that the company will post earnings per share of $0.05 for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.08 EPS and Q4 2025 earnings at $0.09 EPS.

Separately, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Stock Performance

NASDAQ MDXG opened at $9.42 on Monday. MiMedx Group has a 12-month low of $5.47 and a 12-month high of $10.14. The company’s 50 day moving average is $8.35 and its 200-day moving average is $7.17. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The firm has a market cap of $1.38 billion, a P/E ratio of 17.13 and a beta of 1.98.

Institutional Investors Weigh In On MiMedx Group

Hedge funds have recently bought and sold shares of the business. Blue Trust Inc. acquired a new position in MiMedx Group during the 3rd quarter worth $30,000. Point72 Asset Management L.P. acquired a new position in shares of MiMedx Group in the 2nd quarter valued at about $40,000. Point72 DIFC Ltd lifted its stake in MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after acquiring an additional 4,275 shares during the last quarter. Entropy Technologies LP acquired a new stake in shares of MiMedx Group in the 3rd quarter valued at $64,000. Finally, Quest Partners LLC acquired a new stake in shares of MiMedx Group in the second quarter worth about $81,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.